1. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54
- Author
-
Bonaca, Marc P, Wiviott, Stephen D, Morrow, David A, Steg, P Gabriel, Hamm, Christian, Bhatt, Deepak L, Storey, Robert F, Cohen, Marc, Kuder, Julia, Im, KyungAh, Magnani, Giulia, Budaj, Andrzej, Nicolau, José C, Parkhomenko, Alexander, López-Sendón, José, Dellborg, Mikael, Diaz, Rafael, Van de Werf, Frans, Corbalán, Ramón, Goudev, Assen, Jensen, Eva C, Johanson, Per, Braunwald, Eugene, and Sabatine, Marc S
- Subjects
myocardial infarction ,troponin ,ST‐segment elevation myocardial infarction ,antiplatelet therapy ,ticagrelor - Abstract
Background Ticagrelor reduced cardiovascular death, myocardial infarction (MI), or stroke in patients with prior MI in PEGASUS-TIMI 54 (Prevention of Cardiovascular Events [eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin). MI can occur in diverse settings and with varying severity; therefore, understanding the types and sizes of MI events prevented is of clinical importance. Methods and Results MIs were adjudicated by a blinded clinical events committee and categorized by subtype and fold elevation of peak cardiac troponin over the upper limit of normal. A total of 1042 MIs occurred in 898 of the 21 162 randomized patients over a median follow-up of 33 months. The majority of the MIs (76%) were spontaneous (Type 1), with demand MI (Type 2) and stent thrombosis (Type 4b) accounting for 13% and 9%, respectively; sudden death (Type 3), percutaneous coronary intervention-related (Type 4a) and coronary artery bypass graft-related (Type 5) each accounted for
- Published
- 2018